{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', '5.', 'TRIAL OBJECTIVES', 'This trial is designed with 2 parts, SPIMM-301 (PART 1) and SPIMM-301 OLE (PART 2). The', 'objectives of each part are consistent with the trial design.', 'PART 1 is a 24-week, randomized, double-blind, parallel-group, placebo-controlled', 'assessment of the efficacy and safety of single daily SC doses of 40 mg elamipretide', '(vs placebo) administered with the elamipretide delivery system as a treatment for', 'subjects with PMM.', 'PART 2 is an up to 144-week, open-label assessment of the long-term safety and', 'tolerability of single daily SC doses of 40 mg elamipretide administered with the', 'elamipretide delivery system in subjects with PMM.', '5.1.', 'PART 1 Objectives', '5.1.1.', 'Primary Objective', 'The primary objective of PART 1 is to evaluate the effect of single daily SC doses of 40 mg', 'elamipretide administered with the elamipretide delivery system for 24 weeks on the:', 'Distance Walked on the 6MWT', 'Total Fatigue on the Primary Mitochondrial Myopathy Symptom Assessment', '(PMMSA)', '5.1.2.', 'Secondary Objectives', 'Secondary objectives of PART 1 are:', 'To evaluate the effect of single daily SC doses of 40 mg elamipretide administered', 'with the elamipretide delivery system for 24 weeks as measured by changes in the:', '- Fatigue During Activities on the PMMSA', '- Neuro-QoL Short Form Fatigue', '-', 'Most bothersome symptom on the PMMSA', '-', 'Neuro-QoL Fatigue activities of daily living (specific items from the Neuro-QoL', 'Item Bank)', 'To evaluate the safety and tolerability of single daily SC doses of 40 mg elamipretide', 'administered with the elamipretide delivery system for 24 weeks.', '5.1.3.', 'Exploratory Objectives', 'Exploratory objectives of PART 1 are to evaluate the effect of single daily SC doses of 40 mg', 'elamipretide administered with the elamipretide delivery system for 24 weeks as measured by', 'changes in the:', 'Individual symptoms on the PMMSA', 'Alternate version of the PMMSA Total Fatigue Score', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '37']['SPIMM-301 Version 4.0', '15 June 2018', 'Individual items on the Neuro-QoL Fatigue', 'EQ-5D-5L', 'Patient Global Impression (PGI) Scales', 'Clinician Global Impression (CGI) Scales', '5.1.4.', 'Pharmacokinetics (PK)', 'The PK of elamipretide', '5.2.', 'PART 2 Objective', 'The PART 2 objective is to assess the long-term safety and tolerability of single daily SC doses', 'of 40 mg elamipretide administered with the elamipretide delivery system for up to 144 weeks.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '38']['SPIMM-301 Version 4.0', '15 June 2018', '6.', 'INVESTIGATIONAL PLAN', '6.1.', 'SPIMM-301 Overall Trial Design', 'This randomized, double-blind, parallel-group, placebo-controlled trial will enroll approximately', '202 subjects who have PMM. There are 2 parts to this trial.', 'PART 1 is a 24-week, randomized, double-blind, parallel-group, placebo-controlled', 'assessment of the efficacy and safety of single daily SC doses of 40 mg elamipretide (vs', 'placebo) administered with the elamipretide delivery system as a treatment for', 'subjects with PMM. Subjects will be randomized (in a ratio of 1:1) to one of two', 'groups:', '- 24 weeks of single daily SC doses of 40 mg elamipretide or', '-', '24 weeks of single daily SC doses of placebo.', 'PART 2 is an up to 144-week, open-label assessment of the long-term safety and', 'tolerability of single daily SC doses of 40 mg elamipretide administered with the', 'elamipretide delivery system in subjects with PMM. Subjects who continue into', 'PART 2 will receive treatment with 40 mg SC elamipretide administered with the', 'elamipretide delivery system for up to 144 weeks. Thus, treatment during PART 2', 'will be as follows:', '-', 'Subjects who are originally randomized to elamipretide during PART 1 (double-', 'blind treatment) will continue receiving elamipretide during PART 2.', '- Subjects who are originally randomized to placebo during PART 1 (double-blind', 'treatment) will switch to treatment with elamipretide during PART 2.', 'Note that the duration of PART 2 treatment for each subject will be the shortest of the following:', '144 weeks', 'Regulatory approval and commercial availability of the elamipretide delivery system', \"in the subject's respective country\", 'Termination of the clinical development for elamipretide in subjects with PMM.', '6.1.1.', 'PART 1', '6.1.1.1.', 'PART 1 Screening Period', \"Screening will begin with the subject's signature of the informed consent form (ICF) and will\", 'last a minimum of 7 days to a maximum of 28 days. Subjects not previously enrolled in SPIMM-', '300, however, may have a longer screening period for review by the Adjudication Committee to', 'determine their eligibility for study enrollment. Subjects will undergo Screening procedures as', 'described in the PART 1 Schedule of Assessments (Appendix 1) and will be trained and', 'instructed to complete the PMMSA daily during the Screening Period, in an electronic or paper', 'diary, in order to characterize their baseline disease status and to assess compliance. Subjects', 'who complete Screening and continue to meet all trial requirements, including all Inclusion', 'Criteria and none of the Exclusion Criteria, may be randomized (stratified by the', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '39']\n\n###\n\n", "completion": "END"}